Crescent Biopharma (CBIO) Non-Current Assets (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Non-Current Assets of $3.8 million for Q2 2026, up 17.03% year-over-year from $3.2 million in Q2 2025, and up 5.19% quarter-over-quarter from $3.6 million in Q1 2026.
Crescent Biopharma (CBIO) Non-Current Assets (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Non-Current Assets for 14 consecutive years, with $3.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Assets rose 17.03% year-over-year to $3.8 million; the TTM figure through Jun 2026 stood at $14.7 million (up 260.15% YoY), while the FY2025 annual figure was $3.6 million, up 347.48% from the prior year.
- Non-Current Assets rose to $3.8 million in Q2 2026 per CBIO's latest filing, from $3.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $4.0 million in Q1 2022 and bottomed at $52320.0 in Q3 2024.
- Historically, Non-Current Assets has averaged $2.1 million across 5 years, with a median of $1.5 million in 2023.
- Annual changes were most pronounced in 2024 — Non-Current Assets plunged 95.61% — and 2025, when it jumped 6983.33%.
- Crescent Biopharma's Non-Current Assets stood at $1.1 million in 2022, then jumped by 39.22% to $1.5 million in 2023, then slumped by 46.71% to $813000.0 in 2024, then surged by 347.48% to $3.6 million in 2025, then gained by 3.13% to $3.8 million in 2026.
- Business Quant data shows CBIO's Non-Current Assets at $3.8 million in Q2 2026, $3.6 million in Q1 2026, and $3.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | 3.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.75 Mn |
| Mar 31, 2026 | 3.57 Mn |
| Dec 31, 2025 | 3.64 Mn |
| Sep 30, 2025 | 3.71 Mn |
| Jun 30, 2025 | 3.21 Mn |
| Dec 31, 2024 | 813,000.00 |
| Sep 30, 2024 | 52,320.00 |
| Jun 30, 2024 | 561,314.00 |
| Mar 31, 2024 | 937,520.00 |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 1.19 Mn |
| Jun 30, 2023 | 1.45 Mn |
| Mar 31, 2023 | 835,123.00 |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 2.11 Mn |
| Jun 30, 2022 | 3.78 Mn |
| Mar 31, 2022 | 4.00 Mn |
| Dec 31, 2021 | 3.56 Mn |
| Sep 30, 2021 | 3.81 Mn |
| Jun 30, 2021 | 4.06 Mn |